A first patient has enrolled in a Phase 3 trial evaluating cenegermin in treating dry eye disease in people with Sjögren’s syndrome, marking the start of a two-part clinical study program, Dompé, the therapy’s developer, announced. The program will evaluate the safety and efficacy of…
News
Telitacicept (RC18), an experimental therapy being developed by RemeGen, significantly eased disease activity in people with primary Sjögren’s syndrome in a Phase 2 clinical trial, the company announced. “We are very excited to see the positive results from the Phase II clinical trial of telitacicept,” Jianmin Fang,…
Patients with primary Sjögren’s syndrome who experience symptoms such as pain, fatigue, and anxiety are more likely to show a decline in quality of life over time, according to a real-world study from the U.K. The study, “Primary Sjögren’s…
Punctal plugs, which are inserted into the tear ducts to keep the eyes lubricated, are a mainstay of treatment for dry eye in people with primary Sjögren’s syndrome, a South Korean study found. The approach may be combined with additional treatments, but appropriate therapies will depend on the presence…
Combining the anti-inflammatory medicines hydrocortisone and ciclosporin A could help ease eye symptoms in people with Sjögren’s syndrome, according to a new study. The study, “Efficacy of Topical Hydrocortisone in Combination with Topical Ciclosporin A for the Treatment of Dry Eye Disease in Patients with Sjögren…
The experimental oral therapy cenerimod prevented immune cells from entering the salivary glands and reduced gland inflammation in two Sjögren’s syndrome mouse models, a study demonstrated. “These encouraging data suggest that cenerimod may be a promising approach to treating Sjögren’s syndrome,” the scientists said. The study, titled “…
A study has identified concerns common to people with primary Sjögren’s syndrome across five European countries, which researchers hope will help the development of more meaningful patient-reported outcomes and support medical professionals in providing better treatment options. The study, “The Experiences of Functioning and Health of Patients With…
Obstructive sleep apnea (OSA), which occurs when breathing slows or stops repeatedly for short times during sleep, is common among people with primary Sjögren’s syndrome, a study found. Since OSA is associated with an increased risk for cardiovascular problems, fatigue, and other medical problems, physicians should monitor all people with…
A clinical trial at the University of Texas Southwestern Medical Center in Dallas is currently recruiting people with autoimmune diseases, particularly Sjögren’s syndrome, who also have postural orthostatic tachycardia syndrome (POTS). The study, supported by a $150,000 joint grant from the Sjögren’s Foundation and Dysautonomia International, is…
Note: This story was updated Dec. 21, 2021, to note that Sjögren’s syndrome is not a rare disease, being estimated to affect 1-4 million people in the United States. While the vast majority of people with Sjögren’s syndrome are satisfied with their healthcare provider and medication, more than one…
Recent Posts
- Childhood-onset Sjögren’s can cause lasting damage to organs: Study
- Salivary duct treatment eases dry mouth in Sjögren’s disease: Study
- 4 genes linked to inflammatory cell death very active in Sjögren’s
- AI can see what doctors miss to accurately diagnose Sjögren’s
- Worse fatigue tied to more pain in people with Sjögren’s, study finds
- Dazodalibep therapy now in Phase 3 testing for Sjögren’s disease
- Sjögren’s treatment ianalumab shows rapid disease relief in trials
- Sjögren’s patients on nipocalimab report less pain, dryness in trial
- Ouro starts Phase 1b trial of OM336 for Sjögren’s disease treatment
- Telitacicept eases Sjögren’s disease activity in Phase 3 trial